|1.||Giles, Francis J: 7 articles (01/2007 - 02/2002)|
|2.||Kantarjian, Hagop M: 6 articles (01/2007 - 02/2002)|
|3.||Jolivet, J: 6 articles (07/2005 - 04/2000)|
|4.||Gourdeau, Henriette: 5 articles (01/2007 - 12/2002)|
|5.||Jolivet, Jacques: 5 articles (04/2006 - 02/2002)|
|6.||Cortes, Jorge E: 5 articles (12/2003 - 02/2002)|
|7.||Cheng, Yung-Chi: 4 articles (02/2009 - 08/2004)|
|8.||Faderl, Stefan: 4 articles (01/2007 - 03/2003)|
|9.||Giles, Francis: 4 articles (01/2007 - 01/2002)|
|10.||Garcia-Manero, Guillermo: 4 articles (05/2003 - 01/2002)|
11/01/1997 - "BCH-4556 was also effective in inhibiting the growth of rebound CAKI-1 tumors after the administration of a second treatment cycle. "
02/01/2008 - "Preclinical studies showed improved activity with infusions of at least 3 days compared with bolus regimens, especially at concentrations >20 ng/ml. This phase I study tested the feasibility of achieving a troxacitabine steady-state concentration of 20 ng/ml for at least 72 h in patients with solid tumors. "
04/01/2006 - "Plasma samples from 111 cancer patients receiving troxacitabine (0.12-12.5 mg/m(2)) as a 30-minute infusion in phase I trials were used to develop the model with NONMEM. "
12/01/2003 - "Troxacitabine (BCH-4556, l-(-)-OddC, Troxatyl) is a novel beta- l-nucleoside analogue with potent antineoplastic activity both in vitro and in several tumor models in vivo, and is presently in phase II clinical trials. "
10/06/2000 - "beta-l-Dioxolane-cytidine (l-OddC, BCH-4556, Troxacitabine) is a novel unnatural stereochemical nucleoside analog that is under phase II clinical study for cancer treatment. "
|2.||Hematologic Neoplasms (Hematological Malignancy)
01/01/2007 - "Future studies will be needed to address modified dosing according to emerging pharmacokinetic and pharmacodynamic data and combination therapy which may lead to improved clinical benefit for troxacitabine in hematologic malignancies."
06/01/2002 - "Troxacitabine merits further study in patients with hematological malignancies."
02/01/2001 - "Troxacitabine merits further study in hematologic malignancies."
04/01/2007 - "Clinically significant activity has been reported in Phase I studies in patients with advanced hematologic malignancies and has prompted troxacitabine to enter a series of Phase II trials in patients with refractory and relapsed acute myelogenous leukemia."
05/01/2004 - "In this paper we describe mechanisms of action and possible clinical use in the treatment of hematological malignancies of these nucleoside analogs, which are now in different stages of clinical trials, namely tezacitabine, troxacitabine, clofarabine, nelarabine, decitabine, CNDAC and ECyD."
01/01/2007 - "As a single agent, troxacitabine has limited benefit in patients with advanced lymphoproliferative disorders or multiple myeloma. "
01/01/2007 - "A phase II multicenter study of troxacitabine in relapsed or refractory lymphoproliferative neoplasms or multiple myeloma."
08/01/2004 - "To identify nucleoside analogs that may be effective for multiple myeloma (MM), we tested fludarabine, clofarabine, arabinosylguanine, cytarabine, troxacitabine, and gemcitabine in MM cell lines. "
|5.||Neoplasm Metastasis (Metastasis)
08/01/1998 - "In contrast, experimental animals receiving BCH-4556 showed a marked decrease in tumor volume and metastases after the last injection of BCH-4556. "
08/01/1998 - "Treatment with BCH-4556 did not significantly change the development of skeletal metastases and, hence, the time of development of hind limb paralysis. "
08/01/1998 - "Effect of nucleoside analogue BCH-4556 on prostate cancer growth and metastases in vitro and in vivo."
|5.||Vinblastine (Vinblastine Sulfate)
|6.||Multidrug Resistance-Associated Proteins
|10.||formal glycol (dioxolane)
|1.||Heterologous Transplantation (Xenotransplantation)
|2.||Drug Therapy (Chemotherapy)